From lab to mass production: a policy for enabling the licensing of mRNA vaccines
Using the South African vaccine technology transfer hub supported by the WHO as an example, we show that the know-how needed to move mRNA vaccines from prototype to mass-production acts as an invisible barrier to market entry of mRNA vaccines. Overcoming this barrier relies on scarce human capital....
Saved in:
Main Authors: | Andreas Panagopoulos (Author), Katerina Sideri (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nanobiotechnology-Enabled mRNA Stabilization
by: He Xian, et al.
Published: (2023) -
mRNA as a Therapeutics: Understanding mRNA Vaccines
by: Ferdi Oğuz, et al.
Published: (2022) -
Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics
by: Sean C. Semple, et al.
Published: (2022) -
Development of mRNA rabies vaccines
by: Zixin Fang, et al.
Published: (2024) -
Lab-scale siRNA and mRNA LNP manufacturing by various microfluidic mixing techniques - an evaluation of particle properties and efficiency
by: David C. Jürgens, et al.
Published: (2023)